{"id":"W4308834504","doi":"10.1002/art.42391","title":"Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial","year":2022,"lang":"en","type":"article","venue":"Arthritis & Rheumatology","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":248,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Double blind; Placebo; Medicine; Pharmacology; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.01035309,0.001864356,0.009606211,0.003276618,0.001389276,0.0002938555,0.001517691,0.001194103,0.0002278165],"category_scores_gemma":[0.02428992,0.00180344,0.001913436,0.002720545,0.00136097,0.0005691606,0.001633335,0.003161845,0.0007468744],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001144414,"about_ca_system_score_gemma":0.002565236,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007744993,"about_ca_topic_score_gemma":0.0004331027,"domain_scores_codex":[0.9786131,0.005178864,0.006166949,0.002878665,0.003091225,0.004071246],"domain_scores_gemma":[0.9734747,0.0195272,0.002213852,0.002499521,0.0008117961,0.00147294],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6907236,0.01198536,0.02706806,0.005231814,0.004133527,0.01528592,0.05009294,0.0001700665,0.007018143,0.0134558,0.1727687,0.00206611],"study_design_scores_gemma":[0.7612613,0.002787069,0.000002488398,0.00282589,0.0003408977,0.1946093,0.02013123,0.001333679,0.001100485,0.0006143651,0.01477706,0.0002162232],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9175272,0.04828278,0.0002351168,0.0004610811,0.00568362,0.02028,0.0002337984,0.0008244112,0.006471965],"genre_scores_gemma":[0.9619737,0.005391586,0.0002893146,0.0003730895,0.0006114347,0.01766245,0.0005069579,0.0005000277,0.01269149],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1793234,"threshold_uncertainty_score":0.9999108,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02133392397920848,"score_gpt":0.2942335212175657,"score_spread":0.2728995972383573,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}